IDEAL 2a 二期研究:超局灶近距离放疗治疗低中危前列腺癌
该二期研究评估低剂量率超局灶近距离放疗在低中危前列腺癌中的可行性,17例患者中16例达到主要终点(≥95%处方剂量160 Gy覆盖索引肿瘤)。1年随访MRI及索引肿瘤活检未见复发,但未治疗实质发现7例非临床显著癌和1例Gleason 7a癌。
要点
- 超局灶近距离放疗技术可行,16/17例达到主要终点。
- 处方剂量仅覆盖14.5%±6.4%前列腺体积,尿道和直肠受量及毒性可忽略。
- 未治疗实质仍检出7例非临床显著癌和1例Gleason 7a癌。
核心结论
- 近期技术使小MRI靶区的选择性有效近距离放疗成为可能。
研究设计与样本
- 机构审查委员会批准的欧洲临床试验数据库注册的二期方案,2013年10月至2016年8月预选44例主动监测患者。
- 纳入需补充图像引导活检确认单一PI-RADS≥3、Gleason≤7a(3+4)病灶,最终17例接受超局灶近距离放疗。
- 采用Simon最优设计,主要目标为评估将≥95%处方剂量(160 Gy)递送至索引肿瘤的可行性。
主要发现
- 17例治疗患者中16例达到主要目标(符合方案成功)。
- 处方剂量递送至14.5%±6.4%的前列腺体积,尿道和直肠照射及毒性可忽略。
- 1年随访MRI及索引肿瘤活检未见复发。
- 未治疗实质发现7例非临床显著癌和1例Gleason 7a(3+4)癌(行挽救性前列腺切除术)。
关键数值与推荐
- 预选标准:前列腺特异抗原<10 ng/mL、cT1c-cT2a、穿刺Gleason≤6(3+3)、阳性穿刺针数≤3、癌占比≤50%。
- 纳入确认:补充图像引导活检显示单一PI-RADS≥3、Gleason≤7a(3+4)病灶。
- 主要目标:将≥95%处方剂量(160 Gy)递送至索引肿瘤。
临床怎么用
- 超局灶近距离放疗可作为低中危前列腺癌的选择性治疗策略,但需注意未治疗实质存在同时性癌的风险。
局限性
- 样本量小(17例治疗),随访仅1年。
- 预选44例中27例不符合纳入标准,可能限制适用人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Focal therapy of prostate cancer requires precise positioning of therapeutic agents within well-characterized index tumors (ITs). We assessed the feasibility of low-dose-rate ultrafocal brachytherapy. METHODS AND MATERIALS: The present study was an institutional review board-approved European Clinical Trials Database-registered phase II protocol. Patients referred (October 2013 to August 2016) for active surveillance (prostate-specific antigen <10 ng/mL, cT1c-cT2a, Gleason score on referring biopsy specimens ≤6 (3+3), ≤3 positive biopsy cores, ≤50% of cancer) were preselected. Inclusion was confirmed when complementary image-guided biopsy findings informed a single Prostate Imaging Reporting and Data System (PI-RADS) ≥3, Gleason score ≤7a (3+4) lesion. A ultrasound-visible ancillary marker was positioned within the IT using a magnetic resonance imaging (MRI)/3-dimensional transrectal ultrasound (TRUS) elastic fusion-guided system (Koelis). Ultrafocal transperineal delivery of 125I seeds used classic 2-dimensional TRUS (Bard-FlexFocus) and dose optimization (Variseed Treatment Planning System). Following Simon's optimal design, 17 patients were required to assess the feasibility of delivering ≥95% of the prescribed dose (160 Gy) to the IT (primary objective). Adverse events (Common Terminology Criteria for Adverse Events) and quality of life (5-item International Index of Erectile Function, International Prostate Symptom Score) were recorded. One-year control biopsy specimens were obtained from the IT and untreated segments. RESULTS: Of the 44 preselected patients, 27 did not meet the inclusion criteria. Of the 17 ultrafocal brachytherapy-treated patients, 16 met the primary objective (per protocol success). The prescription dose was delivered to 14.5% ± 6.4% of the prostate volume, resulting in negligible urethral and rectal irradiation and toxicity. No recurrence was evidenced on the 1-year follow-up MRI studies or IT biopsy specimens. Seven nonclinically significant cancers and one Gleason score 7a (3+4) cancer (salvage prostatectomy) were observed in the untreated parenchyma. CONCLUSIONS: Recent technology has allowed for selective and effective brachytherapy of small MRI targets.
引用
- Graff P, Portalez D, Lusque A, et al. IDEAL 2a Phase II Study of Ultrafocal Brachytherapy for Low- and Intermediate-risk Prostate Cancer. Int J Radiat Oncol Biol Phys. 2018. PMID: 29510957. doi:10.1016/j.ijrobp.2018.01.066
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。